<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 27-year-old man with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> requiring dialysis underwent allogeneic PBSCT </plain></SENT>
<SENT sid="1" pm="."><plain>The preparative regimen consisted of melphalan, ATG and TLI </plain></SENT>
<SENT sid="2" pm="."><plain>GVHD prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and <z:chebi fb="2" ids="8378">prednisolone</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>He was dialyzed prior to administration of melphalan and at 24 and 72 h after it </plain></SENT>
<SENT sid="4" pm="."><plain>Otherwise, the dialysis schedule was unchanged, at three times a week </plain></SENT>
<SENT sid="5" pm="."><plain>Engraftment was rapid </plain></SENT>
<SENT sid="6" pm="."><plain>Regimen-related toxicity was minimal </plain></SENT>
<SENT sid="7" pm="."><plain>Pharmacokinetic parameters of melphalan were not significantly altered with its plasma half-life 1.5 h </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with <z:hpo ids='HP_0000083'>renal failure</z:hpo> can receive allogeneic HSCT, and a combination of melphalan, ATG and TLI may serve as an alternative to CY and ATG </plain></SENT>
</text></document>